Cristina Meazza, Federica Galaverna, Maria Grazia Petris, Daniele Zama, Milena La Spina, Paola Muggeo, Ottavio Ziino, Monica Cellini, Elena Soncini, Angelica Barone, Raffaella De Santis, Katia Perruccio, Rossella Mura, Silvia Pascale, Federico Mercolini, Simone Cesaro
Prophylaxis of Pneumocystis jiroveci pneumonia (PJP) with trimethoprim/sulfamethoxazole is a standard of care for children with hematologic malignancies, while its use in solid tumor patients is still debated. A retrospective study focusing on the use of PJP prophylaxis in patients with solid tumors was performed among 16 AIEOP centers: 1046/2863 patients did not receive prophylaxis and no cases of PJP were reported.
April 1, 2021: Pediatric Infectious Disease Journal